Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease

BACKGROUND: The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used for the treatment of non‐small cell lung cancer (NSCLC) in clinical practice; however, in patients with preexis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Kanai, Osamu, Kim, Young Hak, Demura, Yoshiki, Kanai, Makiko, Ito, Tsuyoshi, Fujita, Kohei, Yoshida, Hironori, Akai, Masaya, Mio, Tadashi, Hirai, Toyohiro
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026605/
https://ncbi.nlm.nih.gov/pubmed/29782069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12759
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados